Change of Adviser

RNS Number : 8308P

Physiomics PLC

01 April 2009

 



Physiomics plc

('Physiomics' or 'the Company')

Change of Nominated Adviser and Broker

Physiomics is pleased to announce the appointment of WH Ireland Limited as the Company's Nominated Adviser and Broker, with immediate effect.

Enquiries:

Physiomics plc                                                   

Dr Christophe Chassagnole, COO 

[phone]

WH Ireland Limited

David Youngman/Katy Mitchell

[phone]

About Physiomics plc

Physiomics plc (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. As 80-90 per cent of all clinical drug candidates fail to reach the market, estimates1 show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating most important molecular events taking place during the human cell cycle and apoptosis processes. Physiomics developed SystemCell® technology, a multi-cellular environment software, which enables the simulation of population of 'virtual cells'.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

1Tufts Centre Impact Report 2002

 

END

 

 

APPUAUORKWROOAR